Ilia Tikhomirov President and CEO
Ilia is an entrepreneur and inventor of several products under development by Forbius. At Forbius, Ilia built a strong leadership and advisory teams, raised a multiple rounds of financing, and in-licensed additional drug candidates. Prior to Forbius, Ilia occupied positions of increasing responsibility at YM BioSciences Inc. (YM), a publicly traded oncology drug development company that was acquired by Gilead Sciences in a $500 million transaction
. His findings at YM led to the creation of an antibody technology and ultimate spin-out of Forbius from YM prior to the Gilead acquisition. Ilia completed undergraduate and graduate scientific training at the University of Toronto and also holds an MBA from Rotman School of Business.
Maureen O’Connor-McCourt Chief Scientific Officer
Maureen is an expert in the discovery and development of targeted biological therapies. She has published over 100 peer-reviewed manuscripts, including over 50 publications in the TGF-β field. Maureen also holds numerous patents, the majority of which are under active preclinical and clinical development by biotechnology companies. Prior to joining Forbius, Maureen was Principal Research Officer and Section Leader at the Canadian National Research Council (NRC). While at NRC, Maureen served as a Scientific Leader of NRC's Biologics Program, a pan-Canadian network of over 10 research teams. Under her leadership, this program established a successful track record in developing innovative protein therapeutics. Maureen is the recipient of many awards, including the prestigious Gervais-Dionne Award (2012) for her work on “New Cancer Targets and Matching Antibodies for Diagnostic and Therapeutic Use”.
Maureen received her Ph.D. in Biochemistry from the University of Alberta and completed post-doctoral training at the laboratory of Drs. Michael Sporn and Anita Roberts, where TGF- β proteins and their relation to carcinogenesis was newly-discovered.
Paul Nadler M.D., FCP, FACP Chief Medical Officer
Paul has a long and successful track record in clinical development of novel agents for the treatment of cancer and immune system-mediated diseases. He has led development of successfully marketed biologicals, including cytokines and monoclonal antibodies, as well as small molecules. Previously, Paul has served as Chief Medical Officer or Vice President of Medical Research for a variety of biotechnology companies such as Alexion Pharmaceuticals, OSI Pharmaceuticals, Protein Design Labs (including responsibility for preclinical development). As well Paul served with big pharma companies, including Vice President, Scientific Planning and Analysis, and Vice President, Medical Research, with Sandoz Research Institute (Novartis), and Director of Clinical Immunology, and Head, Section of Immunology and Virology, Department of Medical Research with Hoffmann La Roche. Paul has also served on a variety of Medical, Oncology and Scientific Advisory Boards, and advised government agencies, academic centers, and research institutes.
Paul's medical training is in Internal Medicine, Medical Oncology, as well as Clinical Immunology and Allergy. He received his M.D. from Washington University School of Medicine, trained in Internal Medicine at Barnes Hospital/Washington University Medical Center and spent five years in the Immunology Branch of the National Cancer Institute, NIH.
Robert Lutz Chief Development Officer
Bob brings extensive experience in the development of antibody-based therapeutics. Prior to joining Forbius, Bob held various R&D roles over a 23 year span at ImmunoGen, Inc, where most recently he was Vice President of Translational Research and Development, with responsibility for all early stage antibody drug conjugate (ADC) development programs. In addition, Bob was a member of ImmunoGen’s portfolio research committee, served on numerous alliance committees supporting the R&D programs of ImmunoGen’s licensed partners, and was ImmunoGen’s research lead on Genentech’s trastuzumab emtansine (Kadcyla®) program. Earlier, Bob was part of ImmunoGen’s Apoptosis Technology Inc subsidiary where he led the research collaboration leading to the discovery of the BH3 domain of the BCl-2 family of death regulatory proteins. Bob is also the principal consultant for Crescendo Biopharma Consulting where he provides strategic, tactical and operational input to emerging biotech and pharma.
Bob earned his Ph.D. in Biochemistry from Brandeis University and was a research and postdoctoral fellow at the Eleanor Roosevelt Institute in Colorado.
Godfrey Amphlett VP of Manufacturing
Godfrey leads manufacturing activities at Forbius and has over sixteen years of experience heading CMC of biologics and antibody drug conjugates (ADCs). Until 2016, Godfrey was a Vice President at ImmunoGen Inc, a leader in the field of ADCs, where he built and led the Process and Analytical Development department. His group developed and implemented over twenty processes for early stage conjugates and biologics and five processes for late stage and commercial conjugates, including Mirvetuximab Soravtansine and Kadcyla®. Prior to joining ImmunoGen, Godfrey was at Genetics Institute Inc for fifteen years, where he led departments responsible for process, analytical and drug product development of coagulation factors, bone morphogenetic proteins and lymphokines. He was directly involved in submitting successful license applications for five of these products. Godfrey is also the principal at Amphlett Consulting LLC where he advises on process development and manufacturing of biotherapeutics.
Godfrey earned his Ph.D. at the University of Birmingham, U.K. and was a postdoctoral fellow at the University of Notre Dame, Indiana prior to starting his career in the biopharmaceutical industry.
Scott Duncan Director of Intellectual Property
Mr. Duncan is recognized for the quality of his patent consulting services, which he has provided for the past 30 years to a diverse range of biotechnology companies. Prior to this, he built and managed Canada’s largest biotech patent estate during his tenure with Allelix, one of Canada's initial biotech companies, which was acquired by NPS Pharmaceuticals. His responsibilities within that role included the development of patent assets relating to transgenic crops, medicinal chemistry, protein drugs and expression systems, and in vitro diagnostics. Mr. Duncan has been a registered patent agent since 1986, when he qualified magna cum laude while working at a Toronto firm specializing in intellectual property.